Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015

Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015

Mineralocorticoid receptor antagonists (MCRA) are part of standard medical therapy for heart failure (HF). The clinical efficacy of MCRA in patients with systolic HF has been proven by randomized clinical trials. The efficacy of this drug group in patients with chronic HF with preserved left ventric...

Full description

Bibliographic Details
Main Authors:	Yu F Osmolovskaya, I V Zhirov, S N Tereshchenko
Format:	Article
Language:	Russian
Published:	"Consilium Medicum" Publishing house 2015-09-01
Series:	Терапевтический архив
Subjects:	aldosterone mineralocorticoid receptor antagonists chronic heart failure
Online Access:	https://ter-arkhiv.ru/0040-3660/article/view/31823

Similar Items

Mineralocorticoid receptor antagonists in the treatment of patients with heart failure after myocardial infarction and those with chronic heart failure
by: S N Tereshchenko, et al.
Published: (2013-12-01)

Mineralocorticoid Receptor Antagonists
by: Ilaria Spoletini, et al.
Published: (2019-01-01)

Mineralocorticoid receptor antagonists: new extended roles in cardio- and nephroprotection
by: A. M. Esayan, et al.
Published: (2018-04-01)

Mineralocorticoid receptor antagonist use following heart failure hospitalization
by: Jason M. Duran, et al.
Published: (2020-04-01)

Clinical application of mineralocorticoid receptor antagonists in chronic heart failure
by: MG Bubnova
Published: (2014-12-01)

Mineralocorticoid receptor antagonist use after hospitalization of patients with heart failure and post-discharge outcomes: a single-center retrospective cohort study
by: Matthew S. Durstenfeld, et al.
Published: (2019-08-01)

Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
by: Yuta Tezuka, et al.
Published: (2021-03-01)

Prognostic impact of additional mineralocorticoid receptor antagonists in octogenarian heart failure patients
by: Takuro Abe, et al.
Published: (2020-10-01)

Mineralocorticoid receptors in the pathophysiology of vascular inflammation and atherosclerosis.
by: Mary Elizabeth Moss, et al.
Published: (2015-09-01)

Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists
by: Yugar-Toledo JC, et al.
Published: (2017-10-01)

Association of Mineralocorticoid Receptor Antagonist Use With All-Cause Mortality and Hospital Readmission in Older Adults With Acute Decompensated Heart Failure
by: Yaku, Hidenori
Published: (2019)

Effects of spironolactone and eplerenone on left ventricular diastolic function and neurohumoral factors in patients with heart failure
by: N. A. Nuritdinov, et al.
Published: (2020-12-01)

Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction
by: Sho Suzuki, et al.
Published: (2020-10-01)

Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure
by: Nappi J, et al.
Published: (2011-06-01)

Mineralocorticoid Receptor-Dependent Impairment of Baroreflex Contributes to Hypertension in a Mouse Model of Primary Aldosteronism
by: Luo Shi, et al.
Published: (2019-11-01)

Cardiac Mineralocorticoid Receptor and the Na+/H+ Exchanger: Spilling the Beans
by: Irene Lucía Ennis, et al.
Published: (2021-01-01)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
by: Nina Vodošek Hojs, et al.
Published: (2021-06-01)

Les cibles moléculaires du récepteur minéralocorticoïde dans le coeur
by: Gravez, Basile
Published: (2015)

Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis
by: Greg H. Tesch, et al.
Published: (2017-05-01)

PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
by: Stephen eOrena, et al.
Published: (2013-10-01)

Aldosterone and its Antagonists Modulate Elastin Deposition in the Heart
by: Bunda, Severa
Published: (2008)

Aldosterone and its Antagonists Modulate Elastin Deposition in the Heart
by: Bunda, Severa
Published: (2008)

Mineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease
by: Wiktoria Baran, et al.
Published: (2021-09-01)

Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study
by: Michael Blankenburg, et al.
Published: (2019-05-01)

Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice
by: Marie Pieronne‐Deperrois, et al.
Published: (2021-06-01)

Antagonists of mineralocorticoid receptors in the treatment of patients with post-infarced heart failure: the role of eplerenon
by: Vasily V. Kashtalap, et al.
Published: (2019-01-01)

MINERALOCORTICOID RECEPTOR ANTAGONISTS THERAPY IN RESISTANT HYPERTENSION: TIME TO IMPLEMENT NEW GUIDELINES?
by: Giuseppe eMaiolino, et al.
Published: (2015-02-01)

Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology
by: Sofia S. Pereira, et al.
Published: (2021-04-01)

Mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy
by: Ana Sanhueza, et al.
Published: (2020-09-01)

Prévention de l'insuffisance cardiaque par l'antagonisation du récepteur des minéralocorticoïdes dans un contexte de syndrome métabolique : une étude intégrative du phénome, du transcriptiome et du miRNOme
by: Youcef, Gina
Published: (2014)

The Low-Renin Hypertension Phenotype: Genetics and the Role of the Mineralocorticoid Receptor
by: Rene Baudrand, et al.
Published: (2018-02-01)

PATIENT WITH CHRONIC HEART FAILURE. RATIONAL CHOICE OF THERAPY
by: O. M. Drapkina, et al.
Published: (2017-09-01)

European Consensus on use of diuretics in chronic heart failure 2019
by: M. V. Leonova
Published: (2020-05-01)

Aldosterone Inhibits In Vitro Myogenesis by Increasing Intracellular Oxidative Stress via Mineralocorticoid Receptor
by: Jin Young Lee, et al.
Published: (2021-08-01)

MINERALOCORTICOID ANTAGONISM: SELECTIVENESS GIVES MORE OPPORTUNITIES FOR HEART FAILURE MANAGEMENT
by: V. N. Soboleva, et al.
Published: (2015-01-01)

Mineralocorticoid Receptor Signaling Contributes to Normal Muscle Repair After Acute Injury
by: J. Spencer Hauck, et al.
Published: (2019-10-01)

Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction
by: Anker, S.D, et al.
Published: (2022)

A SELECTIVE ANTAGONIST OF MINERALOCORTICOID RECEPTOR EPLERENONE IN CARDIOLOGY PRACTICE
by: B. B. Gegenava, et al.
Published: (2015-09-01)

In the wake of the latest clinical guidelines - mineralocorticoid receptor antagonists in the treatment of chronic heart failure
by: I. V. Zhirov, et al.
Published: (2015-12-01)

Evaluation of aldosterone antagonist utilization in heart failure with reduced and preserved ejection fraction at an academic medical center
by: Bradley D, et al.
Published: (2019-03-01)

Cannot write session to /tmp/vufind_sessions/sess_idrrue1rl9aja8f67g19nub6sf